苏黄止咳胶囊治疗呼吸系统疾病临床应用专家共识
苏黄止咳胶囊广泛用于呼吸系统疾病,已纳入国家基本医疗保险、工伤保险和生育保险药品目录及国家基本药物目录,但存在疗程定义不清、特定人群禁忌不明等问题。本共识由中国中医药学会中成药临床应用共识制定程序严格制定,由中医肺病、呼吸、重症医学及方法学、药学专家共同参与。共识基于PICOS原则通过问卷调查和专家访谈确定临床问题,进行证据评价和GRADE分级,采用名义组技术和GRADE网络方法形成17条推荐和共识建议。共识进一步明确苏黄止咳胶囊治疗咳嗽变异性哮喘和感染后咳嗽的适应证、中医证型、用法及临床安全性,旨在促进规范用药和合理临床应用。
要点
- 共识针对苏黄止咳胶囊治疗咳嗽变异性哮喘、感染后咳嗽等呼吸系统疾病,形成17条推荐和共识建议。
- 共识采用PICOS原则确定临床问题,经证据评价和GRADE分级,以名义组技术和GRADE网络方法形成推荐。
- 共识明确了苏黄止咳胶囊治疗咳嗽变异性哮喘和感染后咳嗽的适应证、中医证型、用法及临床安全性。
- 苏黄止咳胶囊已纳入国家基本医疗保险、工伤保险和生育保险药品目录及国家基本药物目录。
- 共识旨在解决疗程定义不清和特定人群禁忌不明等问题,指导临床正确使用苏黄止咳胶囊。
适用人群与场景
- 咳嗽变异性哮喘患者
- 感染后咳嗽患者
- 其他呼吸系统疾病患者
研究设计与关键结果
- 共识由中医肺病、呼吸、重症医学及方法学、药学专家共同制定,严格遵循中国中医药学会中成药临床应用共识制定程序。
- 共识基于PICOS原则通过问卷调查和专家访谈确定临床问题,进行证据评价和GRADE分级。
- 共识采用名义组技术和GRADE网络方法,形成17条推荐和共识建议。
- 共识明确了苏黄止咳胶囊治疗咳嗽变异性哮喘和感染后咳嗽的适应证、中医证型、用法及临床安全性。
证据类型、等级与局限
- 证据类型:专家共识。
- 共识采用GRADE分级对证据进行评价。
- 局限:原文未报告局限性
对床旁实践的改变
- 共识旨在指导苏黄止咳胶囊治疗咳嗽变异性哮喘、感染后咳嗽等呼吸系统疾病的正确临床使用。
- 共识进一步明确苏黄止咳胶囊的适应证、中医证型、用法及临床安全性,以促进规范用药和合理临床应用。
指南或共识出处
- 苏黄止咳胶囊治疗呼吸系统疾病临床应用专家共识
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Suhuang Zhike Capsules are widely used in clinical practice for the treatment of respiratory diseases and have been included in Medicine Catalogue for National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance and National Essential Medicines List. However, problems remain, such as unclear definitions of treatment courses and unidentified contraindications for certain populations. Therefore, this consensus was developed collaboratively by clinical experts in traditional Chinese medicine(TCM) related to pulmonary diseases, respiratory, and critical care medicine, as well as methodology and pharmacy experts, adhering strictly to the consensus development procedures established by the China Association of Chinese Medicine for clinical application of Chinese patent medicines, with the aim to guide the correct clinical use of Suhuang Zhike Capsules for the treatment of cough variant asthma, post-infectious cough, and other respiratory diseases. This consensus employed questionnaire surveys and expert interviews to identify clinical concerns based on the PICOS principle and conduct evidence evaluation and GRADE grading. Utilizing nominal group techniques and GRADE networking methods, it resulted in 17 recommendations and consensus suggestions. The consensus further clarifies the indications, TCM syndromes, usage, and clinical safety of Suhuang Zhike Capsules in the treatment of cough variant asthma and post-infectious cough, aiming to promote standardized medication use and facilitate the rational clinical application of Suhuang Zhike Capsules.
参考来源
- Ming Y, Huang CR, Yu B, et al. [Expert consensus on clinical application of Suhuang Zhike Capsules in treatment of respiratory diseases]. Zhongguo Zhong Yao Za Zhi. 2025. PMID: 40350858. doi:10.19540/j.cnki.cjcmm.20241015.501
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。